Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma

NCT03352947 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
79
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Collaborators